CONMED Corporation Stock Price and Value Analysis

CONMED Corporation (NasdaqGS:CNMD) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold CONMED Corporation to reach your target.

Target type

CNMD Free Cash Flow Trend

Free Cash Flow trendline for CNMD
Free Cash Flow trendline for CONMED Corporation
CSV

Based on historical returns, we believe that CONMED Corporation can grow its free cash at a rate of about 3%. That's positive!

AdvantagesDisadvantagesNeutral
  • This stock is available at a great discount!
  • This company is solid.
  • This company is making money at a modest rate.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the CNMD Numbers

CNMD Price
(CONMED Corporation stock price per share)
$46.38
[?] CNMD Fair Price
(based on intrinsic value)
$71.83
[?] CNMD Safety Price (based on a variable margin of safety) $46.69
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 5% lower than other Healthcare stocks
[?] PE Ratio versus Industry 483% higher than other Medical Devices stocks
[?] Cash Yield 5.57%
[?] Free Cash Flow Jitter 50%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 1,861,112 shares shorted. With 29,513,933 shares available for purchase and an average trading volume over the past 10 trading days of 299,600, it would take at least 6.2 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2009 816956 3.6
2010 816956 20.2
2011 816956 85.1
2012 816956 76.4
2013 816956 62.2
2014 816956 47.6
2015 816956 33.3
2016 816956 22.9
2017 816956 50.3
2018 816956 59.8
2019 816956 79.3
2020 816956 49.1
2021 816956 96.3
2022 816956 16.1
2023 816956 108
2024 816956 151
2025 816956 153

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 16 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled $1,373 million against net income of $638 million, or 2.15 times. Net income was negative in 1 of the 17 years, and those years are left out of the ratio.

In 2025, operating cash flow was 3.63 times net income, compared with 3.85 times for the earliest three years (2009 to 2011).

In 2025, capital expenditures were $19.8 million, 11.6% of operating cash flow of $171 million, which leaves an estimated $151 million after capex. Across the 17 years with reported capex, it averaged 20.6% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2009 12.1 25 21.4 2.06
2010 30.3 38.2 14.7 1.26
2011 0.8 103 17.6 136.96
2012 40.5 95.2 21.5 2.35
2013 35.9 80.9 18.4 2.25
2014 32.2 65.2 15.4 2.02
2015 30.5 50.9 15 1.67
2016 14.7 39.9 14.8 2.72
2017 55.5 65.6 12.8 1.18
2018 40.9 74.7 16.5 1.83
2019 28.6 95.1 20.1 3.32
2020 9.5 64.5 13 6.78
2021 62.5 112 14.9 1.79
2022 -80.6 33.4 21.8 n/a
2023 64.5 125 19 1.94
2024 132 167 13.1 1.26
2025 47.1 171 19.8 3.63

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $785 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $233 million, 29.7% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 9 of those 10 years.

In 2025, dividends paid were $24.7 million, 16.2% of estimated free cash flow of $153 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 22.9 22.2 n/a 22.2 97.2%
2017 50.3 22.3 n/a 22.3 44.4%
2018 59.8 22.4 n/a 22.4 37.5%
2019 79.3 22.6 n/a 22.6 28.5%
2020 49.1 22.8 n/a 22.8 46.5%
2021 96.3 23.3 n/a 23.3 24.1%
2022 16.1 24 n/a 24 148.7%
2023 108 24.5 n/a 24.5 22.8%
2024 151 24.7 n/a 24.7 16.4%
2025 153 24.7 n/a 24.7 16.2%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $695 million in 2009 and $1,375 million in 2025, a compound annual growth rate of 4.4% over 16 years.

Revenue rose 5.2% from 2024 to 2025.

Our estimated free cash flow was $153 million in 2025, 11.1% of revenue. In 2009 the estimated margin was 0.5%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 695 3.6 0.5%
2010 714 20.2 2.8%
2011 725 85.1 11.7%
2012 767 76.4 10.0%
2013 763 62.2 8.2%
2014 740 47.6 6.4%
2015 719 33.3 4.6%
2016 764 22.9 3.0%
2017 796 50.3 6.3%
2018 860 59.8 7.0%
2019 955 79.3 8.3%
2020 862 49.1 5.7%
2021 1,011 96.3 9.5%
2022 1,045 16.1 1.5%
2023 1,245 108 8.6%
2024 1,307 151 11.5%
2025 1,375 153 11.1%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $40.8 million against total liabilities of $1,293 million, or 3.2% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 55.6% of total assets in 2025, compared with 40.5% in 2010, an increase of 15.1 percentage points.

Stockholders equity was $1,033 million in 2025, compared with $587 million in 2010, a rise of 76.1%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 7.8% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 986 12.4 399 587
2011 936 26 363 573
2012 1,079 23.7 472 607
2013 1,091 54.4 484 606
2014 1,098 66.3 517 581
2015 1,102 72.5 517 585
2016 1,329 27.4 748 581
2017 1,358 32.6 727 631
2018 1,369 17.5 707 662
2019 1,775 25.9 1,065 710
2020 1,752 27.4 1,043 709
2021 1,766 20.8 981 785
2022 2,298 28.9 1,552 746
2023 2,300 24.3 1,466 834
2024 2,306 24.5 1,344 963
2025 2,326 40.8 1,293 1,033

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $46.38, our model's value equals that price if free cash flow grows an average of -13.1 percent a year over the 10 projection years. Our model assumes 3.3 percent a year for this stock, so the price implies growth of -13.1 percent, which is below the 3.3 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

A negative rate means the price matches our model's value only if free cash flow shrinks by that average each year over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $77 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $37.10 below range
Current price $46.38 -13.1%
20 percent above the current price $55.66 -4.6%
Our model (stored fair price) $71.83 3.3%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

At $46.38, CONMED Corporation trades below our safe value estimate of $46.69 and our fair value estimate of $71.83.

Every one of the 17 fiscal years we have for CONMED Corporation under its current filer shows positive free cash flow.

The latest three years average $137 million in free cash flow against $36.3 million for the earliest three, which is a sharp rise.

Free cash flow is volatile from year to year, with a variability measure of 50%.

Our value investing guide explains how to test these numbers against the filings themselves.

No dividend yield is recorded for CONMED Corporation in our data.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 5% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 483% above the average for stocks in the Medical Devices industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Devices industry, the ones closest in market capitalization to CONMED Corporation, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
CONMED Corporation (CNMD) 1,382 19.2 - 5.6% 35% below
LeMaitre Vascular (LMAT) 1,684 27.1 1.3% - 328% above
IRadimed Corporation (IRMD) 1,036 43.3 1.0% - 995% above
Tactile Systems Technology (TCMD) 573 24.9 - - 162% above
UFP Technologies (UFPT) 2,253 29.7 - 0.1% 395% above
InfuSystem Holdings (INFU) 287 32.6 - - 402% above
Utah Medical Products (UTMD) 198 20.8 1.7% 6.7% 75% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 816956.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: CNMD annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in CNMD

Does CONMED Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: CNMD

This example shows how we apply the Trendshare checklist to CNMD: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 46.38
    • Market cap: $1.4B
    • EPS: 2.41
  2. Step 2 — Valuation checks

    • P/E: 19.245
    • FCF yield: 5.6%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.